AICAR for Endurance: What the Mouse Data Shows (2026)

Fat and Glucose Oxidation (Rat Data)

The metabolic case for AICAR rests on rodent muscle experiments. A 2005 Journal of Physiology study by Smith and colleagues reported that AICAR simultaneously raised both fatty-acid oxidation and glucose oxidation in resting rat soleus muscle, via AMPK. Mechanistically, AMPK phosphorylates acetyl-CoA carboxylase, which lowers malonyl-CoA and releases the brake on CPT-1 so more fat enters the mitochondria to be burned; in parallel, AMPK drives GLUT4 to the cell surface for insulin-independent glucose uptake.

This is the mechanistic basis for the "fat loss" and "glucose disposal" claims attached to AICAR. But Smith's 2005 findings describe isolated rat muscle, not body-composition change in humans. There is no controlled human trial reporting that AICAR reduces body fat or improves glucose control in people. Community sources sometimes describe modest fat loss over four to eight weeks, often stacking AICAR with GW-501516 (cardarine) in a pattern traced back to the mouse Narkar protocol; those are unverified anecdotes from unregulated settings, not trial outcomes, and no human study corroborates them.

Mitochondrial Biogenesis via PGC-1alpha

The link between AMPK and building new mitochondria is well established at the molecular level. A 2007 PNAS study by Jager and colleagues reported that AMPK directly phosphorylates PGC-1alpha — the master regulator of mitochondrial biogenesis — in skeletal muscle, which helps explain how AMPK activation shifts muscle toward a more oxidative, endurance-type phenotype.

Because AICAR activates AMPK directly, this PGC-1alpha pathway is the plausible mechanistic route from an AICAR dose to more mitochondria. Jager's 2007 work characterizes the signaling step itself, in muscle-cell and mouse systems; it is a mechanism paper, not evidence that injected AICAR increases mitochondrial density or performance in humans.

What the Human Data Actually Shows

The only rigorous human trials of this molecule tested acadesine — the same compound — as a cardioprotective agent during heart surgery, not as a fitness aid. Early signals looked promising: a 1997 JAMA meta-analysis by Mangano pooled five randomized trials in roughly 4,000 CABG patients and reported an early signal of reduced perioperative heart attack and cardiac death.

That signal did not hold up. The definitive Phase 3 trial, RED-CABG, reported by Newman and colleagues in JAMA in 2012, enrolled roughly 3,000 patients and found no benefit — event rates were essentially identical between acadesine and placebo (about 5.1% versus 5.0%) — and the trial was stopped for futility. This negative result is why acadesine was never approved for any indication. It is the single most rigorous human test of the molecule, and it failed its endpoint. On the safety side, the acadesine trials documented asymptomatic increases in uric acid (AICAR is metabolized to uric acid), transient rises in creatinine, and infusion-related low blood pressure; long-term safety of chronic AICAR in healthy people has never been studied.

How AICAR Relates to MOTS-c

A useful way to frame AICAR is alongside MOTS-c, a compound that reaches the same destination by a different road. A 2015 Cell Metabolism study by Lee and colleagues reported that MOTS-c activates AMPK indirectly — it interferes with the folate cycle, which causes endogenous AICAR and ZMP to accumulate inside the cell, and that buildup activates AMPK. In other words, MOTS-c works partly by generating the body's own AICAR-like signal, while injected AICAR supplies a synthetic AMP look-alike directly.

The two share the same downstream outputs — GLUT4, fatty-acid oxidation, PGC-1alpha, oxidative muscle programming — and they share the same evidence gap. Neither has controlled human data establishing physique or performance benefits, and both are prohibited in sport by WADA at all times. For a fuller breakdown of the peptide side of that pathway, see the MOTS-c benefits article.